159 related articles for article (PubMed ID: 32195378)
1. The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma.
Chan J; Jayamanne D; Wheeler H; Khasraw M; Wong M; Kastelan M; Guo L; Back M
Clin Transl Radiat Oncol; 2020 May; 22():33-39. PubMed ID: 32195378
[TBL] [Abstract][Full Text] [Related]
2. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.
Back M; Gzell CE; Kastelan M; Guo L; Wheeler HR
Neurooncol Pract; 2015 Mar; 2(1):48-53. PubMed ID: 26034641
[TBL] [Abstract][Full Text] [Related]
3. Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma.
Cuncannon M; Wong M; Jayamanne D; Guo L; Cove N; Wheeler H; Back M
BMC Cancer; 2019 May; 19(1):445. PubMed ID: 31088401
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
Fleischmann DF; Jenn J; Corradini S; Ruf V; Herms J; Forbrig R; Unterrainer M; Thon N; Kreth FW; Belka C; Niyazi M
Radiother Oncol; 2019 Sep; 138():99-105. PubMed ID: 31252301
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.
Kulinich DP; Sheppard JP; Nguyen T; Kondajji AM; Unterberger A; Duong C; Enomoto A; Patel K; Yang I
Acta Neurochir (Wien); 2021 Jul; 163(7):1921-1934. PubMed ID: 33796887
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
7. Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.
Marwah R; Xing D; Squire T; Soon YY; Gan HK; Ng SP
J Neurooncol; 2023 Sep; 164(3):505-524. PubMed ID: 37733174
[TBL] [Abstract][Full Text] [Related]
8. Outcome of Second Line Treatment of Recurrent High- Grade Glioma by re-Irradiation or Bevacizumab-based Chemotherapy: A Cross Sectional Study.
Anvari K; Shahabadi M; Welsh JS; Javadinia SA; Zarei E
Asian Pac J Cancer Prev; 2023 May; 24(5):1507-1511. PubMed ID: 37247269
[TBL] [Abstract][Full Text] [Related]
9. Re-irradiation for recurrent or second primary head and neck cancer.
Lee HI; Kim JH; Ahn SH; Chung EJ; Keam B; Eom KY; Jeong WJ; Kim JW; Wee CW; Wu HG
Radiat Oncol J; 2021 Dec; 39(4):279-287. PubMed ID: 34986549
[TBL] [Abstract][Full Text] [Related]
10. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
[TBL] [Abstract][Full Text] [Related]
11. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists.
Furlan C; Arcangeli S; Avanzo M; Mirri MA; Munoz F; Giudici S; Perrone A; Amelio D; Tomio L; Draghini L; Deli AM; Pavanato G; Giuliano FM; Pontoriero A; Ciammella P; Navarria P; Iannalfi A; Buglione M; Guida C; Cammelli S; Iorio V; Cardinali M; Genovesi D; Barsacchi L; Balducci M; Bagnoli R; Berti F; Montesi G; Pasqualetti F; Bonome P; Santoni R; Doino D; Schirru P; Pinzi V; Borzillo V; Ferrarese F; Ferro M; Cicco L; Krengli M; Scoccianti S; Donato V
Tumori; 2018 Dec; 104(6):466-470. PubMed ID: 28315510
[TBL] [Abstract][Full Text] [Related]
12. Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors.
You WC; Lee HD; Pan HC; Chen HC
Sci Rep; 2023 Jun; 13(1):9442. PubMed ID: 37296207
[TBL] [Abstract][Full Text] [Related]
13. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ
J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306
[TBL] [Abstract][Full Text] [Related]
14. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
[TBL] [Abstract][Full Text] [Related]
15. How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment.
Massimino M; Vennarini S; Barretta F; Colombo F; Antonelli M; Pollo B; Pignoli E; Pecori E; Alessandro O; Schiavello E; Boschetti L; Podda M; Puma N; Gattuso G; Sironi G; Barzanò E; Nigro O; Bergamaschi L; Chiaravalli S; Luksch R; Meazza C; Spreafico F; Terenziani M; Casanova M; Ferrari A; Chisari M; Pellegrini C; Clerici CA; Modena P; Biassoni V
J Neurooncol; 2022 Sep; 159(2):437-445. PubMed ID: 35809148
[TBL] [Abstract][Full Text] [Related]
16. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
[TBL] [Abstract][Full Text] [Related]
17. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.
Kline C; Liu SJ; Duriseti S; Banerjee A; Nicolaides T; Raber S; Gupta N; Haas-Kogan D; Braunstein S; Mueller S
J Neurooncol; 2018 Dec; 140(3):629-638. PubMed ID: 30206764
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
19. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
[TBL] [Abstract][Full Text] [Related]
20. Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.
Müller K; Henke G; Pietschmann S; van Gool S; De Vleeschouwer S; von Bueren AO; Compter I; Friedrich C; Matuschek C; Klautke G; Kortmann RD; Hundsberger T; Baumert BG
J Neurooncol; 2015 Sep; 124(2):325-32. PubMed ID: 26070556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
